Open AccessCAR T-cell immunotherapy of B-cell malignancy: the story so far
Author(s) -
Leena Halim,
John Maher
Publication year - 2020
Publication title -
therapeutic advances in vaccines and immunotherapy
Language(s) - English
Resource type - Journals
eISSN - 2515-1363
pISSN - 2515-1355
DOI - 10.1177/2515135520927164
Subject(s) - chimeric antigen receptor , immunotherapy , medicine , cd19 , clinical trial , cell therapy , t cell , antigen , immunology , cell , biology , immune system , genetics
Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies. Promising results from pivotal anti-CD19 CAR T-cell phase II trials have led to landmark approvals of two CD19-specific CAR T-cell products by the United States Food and Drug Administration and European Medicines Agency. However, several issues associated with CAR T-cell treatment remain unresolved, such as the management of severe toxicities and the frequent occurrence of both antigen-positive and antigen-negative relapse. Nonetheless, pre-clinical research is advancing at an unprecedented pace to develop innovative solutions to address these issues. Herein, we summarise recent clinical developments and outcomes of CD19-targeted CAR T-cell immunotherapy and discuss emerging strategies that may further improve the success, safety and broadened applicability of this approach.